Dan is the chairman of our Board of Directors and a Venture Partner at Third Rock Ventures. He brings more than 25 years of experience serving in management and board positions in the biotechnology and pharmaceutical industries. Dan spent five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of ERBITUX® (cetuximab), an important new cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. More recently, Dan was executive chairman of the board for Avila Therapeutics and Stromedix, which were successfully acquired by Celgene and Biogen Idec, respectively. In addition to Blueprint Medicines, Dan is currently a member of the board of directors for Bluebird Bio, Ember Therapeutics and BIND Biosciences. Dan received his B.A. in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
CEO, President and Member of the Board of Directors
Jeff has more than 15 years of experience in leadership roles in the biopharmaceutical industry. He joined Blueprint Medicines after a successful tenure as president of Algeta US, where he oversaw the commercial and business functions during a period of exponential growth in staff and revenue. Under his leadership, Algeta gained FDA approval and launched prostate cancer drug XOFIGO® (radium Ra 223 dichloride) on an expedited timeline, exceeding revenue forecasts and ultimately supporting a successful acquisition by Bayer. Prior to Algeta, Jeff held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the US hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.
Partner, Third Rock Ventures
Alexis is a co-founder of Blueprint Medicines and a member of our Board of Directors. He is a successful biotechnology entrepreneur with more than 20 years of experience launching, building and operating innovative science-based organizations. Alexis joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies, with a particular focus in personalized medicine. He co-founded Foundation Medicine and served as the company’s interim CEO. He also launched and served as interim CEO and currently is chairman of Warp Drive Bio. Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its chief executive officer and bringing the company public on NASDAQ just five years later. He has raised more than $1 billion in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard University, where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the Massachusetts Institute of Technology (MIT) Technology Review Innovator of the Year in 2003. He was also chosen as the New England Entrepreneur of the Year in Life Sciences in 2003 and was honored as a Presidential Scholar in 1989. Alexis serves on the board of the Biotechnology Industry Organization and is an overseer at the Boston Museum of Science. He holds a B.S. in chemistry from the University of Chicago, and completed his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard.
CEO, President and Member of the Board of Directors, Lexicon Pharmaceuticals, Inc.
Lonnel is a seasoned pharmaceutical executive with nearly 30 years of industry-related experience. He currently serves as president and chief executive officer and a member of the board of directors of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a biopharmaceutical company focused on the development of breakthrough therapies for the treatment of type 1 and type 2 diabetes and carcinoid syndrome. Prior to joining Lexicon in July 2014, Lonnel served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., from 1996 through June 2014, including as chief executive officer of Eisai Inc. from 2010 to June 2014. In this role, Lonnel helped establish Eisai as a leading innovator of medicines for oncology and specialty therapeutic areas, and he oversaw the expansion of Eisai’s business across the Americas and improved profitability for all of its U.S.-based operating units. In addition, he served as president and chief operating officer of Eisai Inc. from 2004 to 2010 and led the diversification of its business through over $5 billion in strategic acquisitions and licensing and partnership transactions. Lonnel also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. He holds a B.S. from Oakland University.
Professor of Medicine at Harvard Medical School, Director of the Center for Sarcoma and Bone Oncology, and Physician at the Dana-Farber Cancer Institute
George is a member of our Board of Directors and a scientific advisor to the company. He is a Professor of Medicine at Harvard Medical School, Director of the Center for Sarcoma and Bone Oncology, and a physician at the Dana-Farber Cancer Institute (DCFI). George and the multidisciplinary team at Dana-Farber/Harvard Cancer Center have developed one of the largest centers of excellence for research and care of sarcoma patients, focusing on the development of novel therapies. His research and clinical interests have centered on mechanism-based drug development for solid tumors, with a particular emphasis on molecularly defined subsets of sarcomas, such as gastrointestinal stromal tumors. He has contributed to the development of numerous kinase cancer therapies, including Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Zelboraf (vemurafenib) and Votrient (pazopanib) as well as other new targeted therapies in development. George serves as chair of the medical advisory board for the Sarcoma Foundation of America, as well as several scientific and editorial advisory boards. With an interest in internet-based patient support, he serves on the Medical Advisory Board of American Society of Clinical Oncology’s CancerNet and CancerCommons.org. George has an undergraduate degree in biochemistry from Harvard University and an M.D. from Stanford University School of Medicine, completed his residency in internal medicine at the University of Washington Hospitals in Seattle and completed a fellowship in medical oncology at DCFI.
Associate Professor of Medicine, Harvard Medical School
Mark is an industry leader with deep expertise in the development of innovative therapies for cancer and rare diseases. He was most recently Senior Vice President of Product Development at Synageva BioPharma, where he was responsible for clinical development, until the company’s acquisition by Alexion Pharmaceuticals in 2015. Prior to joining Synageva in 2011, Mark spent 15 years at Genzyme Corp., serving in increasing roles of responsibility, most recently as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While there, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Mark is a board certified medical oncologist and hematologist. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. He is an Associate Professor of Medicine at Harvard Medical School and is an author on more than 50 published papers. He currently serves on the boards of several biotech companies, including Idera, ImmunoGen and GlycoMimetics. Mark received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School.
Founder, Granite Biopharma LLC
Nick is one of our scientific founders and a member of our Board of Directors. He is a renowned expert in the field of kinase drug discovery and development for cancer. In 2009, Nick and our other scientific founders, Brian Druker, M.D., and Charles L. Sawyers, M.D., were awarded the Lasker-DeBakey Award for Clinical Medical Research for their role in the discovery and development of Gleevec® (imatinib), a targeted kinase inhibitor that transformed chronic myeloid leukemia from a fatal cancer into a manageable disease. Dr. Lydon founded and currently runs the consulting firm Granite Biopharma LLC. He previously served as vice president, Small Molecule Drug Discovery at Amgen Inc. Prior to Amgen, he was the CEO and founder of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors. Amgen acquired Kinetix in 2000. Prior to Kinetix, Nick worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Gleevec. He began his pharmaceutical career at Schering-Plough Corp., where his research involved studies on recombinant interferons. Nick has been awarded the Japan Prizes for his work on Gleevec. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation. He earned a BS in biochemistry and zoology from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.
Charles brings more than 30 years of experience in biopharmaceutical financial management and strategic business operations. Most recently, Charlie served as the president and chief executive officer and a member of the board of directors of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) Prior to joining Aurinia, Charlie served as the vice president and chief financial officer of ViroPharma, a global biopharmaceutical company with $500 million in revenues, until the company was acquired by Shire plc in January 2014. In this role, he oversaw all aspects of finance, including financial analysis and reporting, tax, treasury and investor relations, as well as strategic business planning and information technology. Before joining ViroPharma in 2008, Charles was executive vice president and CFO, as well as interim co-chief executive officer, for Endo Pharmaceuticals, a specialty pharmaceutical company with $1.3 billion in revenues. He previously held finance positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia Corp., Novartis AG and Bristol-Myers Squibb Co. Charles also serves as a director and chair of the audit committees of Vitae Pharmaceuticals and Nabriva Therapeutics, AG. He holds an MBA from Rutgers’s University and a BS from Saint Joseph’s University.
Former CMO of Medivation, Inc.
Dr. Seely is currently the President & Chief Executive Officer of Myovant Sciences, Inc. She served as chief medical officer of Medivation, Inc. from March 2005 until her retirement in October 2015, including as senior vice president and chief medical officer from January 2009 to October 2015. In this role, she led the development of Xtandi (enzalutamide) from the first-in-human clinical trial through marketing approval and participated actively in Phase 3 drug development collaborations with Pfizer Inc. and Astellas Pharma US, Inc., as well as the acquisition of talazoparib from BioMarin Pharmaceutical Inc. Prior to joining Medivation, from September 2002 to March 2005, Dr. Seely served as vice president of clinical development at Anesiva, Inc., formerly Corgentech Inc., a biomedical company where she participated in a Phase 3 deal with Bristol-Myers Squibb. Dr. Seely previously served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002, and from 2000 to 2001, Dr. Seely served as vice president of clinical development at ProDuct Health, Inc., a privately held medical device company prior to its acquisition by Cytyc. Dr. Seely began her career as associate director of clinical development at Chiron Corporation. Dr. Seely received a B.A. in journalism from the University of Oklahoma and an M.D. from the University of Oklahoma College of Medicine. She completed her residency and was chief resident in internal medicine at Yale-New Haven Hospital and her fellowship in endocrinology and metabolism at the University of California, San Diego.